Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

Kabashima, 2018, Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study, J Allergy Clin Immunol, 142, 1121, 10.1016/j.jaci.2018.03.018 Ruzicka, 2017, Anti-interleukin-31 receptor A antibody for atopic dermatitis, N Engl J Med, 376, 826, 10.1056/NEJMoa1606490 Nemoto, 2016, Br J Dermatol, 174, 296, 10.1111/bjd.14207 Jones, 2018, Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer, Nat Rev Immunol, 18, 773, 10.1038/s41577-018-0066-7 Bilsborough, 2006, IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis, J Allergy Clin Immunol, 117, 418, 10.1016/j.jaci.2005.10.046 Cevikbas, 2014, A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1, J Allergy Clin Immunol, 133, 448, 10.1016/j.jaci.2013.10.048 Kato, 2014, Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis, J Dermatol Sci, 74, 229, 10.1016/j.jdermsci.2014.02.009 Nobbe, 2012, IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis, Acta Dermatovenereol, 92, 24 Sonkoly, 2006, IL-31: a new link between T cells and pruritus in atopic skin inflammation, J Allergy Clin Immunol, 117, 411, 10.1016/j.jaci.2005.10.033 Szegedi, 2012, Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin, Exp Dermatol, 21, 431, 10.1111/j.1600-0625.2012.01487.x Feld, 2016, The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves, J Allergy Clin Immunol, 138, 500, 10.1016/j.jaci.2016.02.020 Meng, 2018, New mechanism underlying IL-31-induced atopic dermatitis, J Allergy Clin Immunol, 141, 1677, 10.1016/j.jaci.2017.12.1002 Bagci, 2018, IL-31: a new key player in dermatology and beyond, J Allergy Clin Immunol, 141, 858, 10.1016/j.jaci.2017.10.045 Singh, 2016, IL-31-driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin-barrier function, PLoS One, 11, e0161877, 10.1371/journal.pone.0161877 Silverberg, 2015, Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study, J Invest Dermatol, 135, 56, 10.1038/jid.2014.325 Silverberg, 2018, Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study, Ann Allergy Asthma Immunol, 121, 340, 10.1016/j.anai.2018.07.006 Chrostowska-Plak, 2013, Relationship between itch and psychological status of patients with atopic dermatitis, J Eur Acad Dermatol Venereol, 27, e239, 10.1111/j.1468-3083.2012.04578.x Silverberg, 2017, Atopic dermatitis treatment: current state of the art and emerging therapies, Allergy Asthma Proc, 38, 243, 10.2500/aap.2017.38.4054 Armstrong, 2019, Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis, PLoS One, 14, e0210517, 10.1371/journal.pone.0210517 Vermeire, 2014, Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial, Lancet, 384, 309, 10.1016/S0140-6736(14)60661-9 Fontenot, 2013, A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth, Mol Cancer Ther, 12, 685, 10.1158/1535-7163.MCT-12-1066 Vermeire, 2017, Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, 390, 135, 10.1016/S0140-6736(17)30930-3 Saini, 2011, A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria, J Allergy Clin Immunol, 128, 567, 10.1016/j.jaci.2011.06.010